Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-CODOX-M/IVAC in High-Risk DLBCL
NCT00974792Phase 2Unknown
- Sponsor
- Cancer Research UK
- Start
- Jan 2006
- Primary completion
- May 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in diffuse large B-cell lymphoma (DLBCL), sponsored by Cancer Research UK. Status: unknown.
02
Drugs
rituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT00974792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00974792.